COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update

por Jack, Dominic, Damian, Doris, Nolting, Axel, Galazka, Andrew
Publicado 2021

Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update

por Jack, Dominic, Damian, Doris, Nolting, Axel, Galazka, Andrew
Publicado 2021

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers

por Stuve, Olaf, Soelberg Soerensen, Per, Leist, Thomas, Giovannoni, Gavin, Hyvert, Yann, Damian, Doris, Dangond, Fernando, Boschert, Ursula
Publicado 2019

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety

por Giovannoni, Gavin, Galazka, Andrew, Schick, Regina, Leist, Thomas, Comi, Giancarlo, Montalban, Xavier, Damian, Doris, Dangond, Fernando, Cook, Stuart
Publicado 2020

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study

por Freedman, Mark S, Leist, Thomas P, Comi, Giancarlo, Cree, Bruce AC, Coyle, Patricia K, Hartung, Hans-Peter, Vermersch, Patrick, Damian, Doris, Dangond, Fernando
Publicado 2017

Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study

por Freedman, Mark S, Coyle, Patricia K, Comi, Giancarlo, L Scarberry, Susan, Damian, Doris, Hyvert, Yann, Dangond, Fernando, Galazka, Andrew, Jack, Dominic, Lebson, Lori A, Leist, Thomas P
Publicado 2021